Skip to content

Dexamethasone Preoperative for Patients Undergoing Laparoscopy for Suspected Appendicitis

Dexamethasone Preoperative for Patients Undergoing Laparoscopy for Suspected Appendicitis

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02415335
Enrollment
119
Registered
2015-04-14
Start date
2015-04-30
Completion date
2015-10-31
Last updated
2016-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suspected Appendicitis

Brief summary

For elective abdominal surgery preoperative administration of 8 mg dexamethasone reduces the incidents of postoperative nausea and vomiting (PONV). Whether preoperative administration of 8 mg dexamethasone reduces PONV for patients having acute abdominal surgery has not been established. The investigators wish to see if preoperative administration of 8 mg dexamethasone minimum 30 minutes prior to a diagnostic laparoscopy for suspected appendicitis will reduce the incidents of PONV by 50%. Of secondary interest the investigators want to see if 8 mg dexamethasone preoperative can reduce pain, reduce opioid consumption, postoperative fatigue, duration of time until resumption of work and resumption of normal daily activities, and enhanced the quality of recovery.

Detailed description

Eligible patients undergoing a diagnostic laparoscopy for suspected appendicitis will be randomized to receive placebo or 8 mg dexamethasone intravenously minimum 30 minutes prior to the operation. Randomization will be done by envelope randomization. We would expect that 60% of the patients would experience postoperative nausea or vomiting (PONV) during the first 24-32 hours postoperatively. To show a 50% reduction in the incidents of PONV during the first 24-32 hours postoperatively (with a power of 80%, a significant level of 5% and a loss to follow up of 20%) we need 60 patients in each arm. So a total of 120 patients are to be randomized 1:1. Both sites use paper Case Report Forms (CRF). The trial will be monitored by the regional GCP (Good Clinical Practice) unit and adhere to GCP guidelines. Patients are assessed by self reporting questionnaires preoperatively and postoperatively after 2-10 hours, 8-16 hours, 24-32 hours, on postoperative day (POD) 2, POD 3, POD 7, POD 14 and POD 30. Preoperative anxiety recorded by a VAS scale, Pain Catastrophizing Scale and Hospital anxiety and depression scale are recorded by the preoperative questionnaire. A short telephone interview will be done during the first postoperative day regarding duration of abdominal pain prior to admission, social status regarding children and whether they living with another adult, smoking status, use of sleep medication or use of psychopharmacy a minimum of 7 days prior to the operation, physical level of normal daily activities, physical level of work, educational and occupational background. Other demographics such as height, weight, ASA class, age, last CRP prior to the operation, duration of the operation, date and time of admission, date and time of discharge are registered through the electronic patient record files. Pathology of any removed tissue are registered trough the pathology report. Diagnosis at the operation, preformed procedure, whether the preforming surgeon was supervised, number of identical procedures preformed previous by the surgeon or the surgeons supervisor (if supervised) will be recorded in the patients CRF by the preforming surgeon. Pre-, intra- and post-operative pain medication, antiemetics and antibiotics are recorded through the electronic patient medication files. Postoperative complications and adverse events are recorded through the electronic patient record files and by telephone interview. To ensure a high completion rate, patients are contacted by telephone at each registration time postoperatively. Parametric or non-parametric statistical analysis will be used when appropriate.

Interventions

DRUGdexamethasone phosphate

Intravenously administration minimum of 30 minutes preoperatively.

Intravenously administration minimum of 30 minutes preoperatively

Sponsors

Zealand University Hospital
CollaboratorOTHER
Nordsjaellands Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Scheduled for a diagnostic laparoscopy for suspected appendicitis * ASA clas I-III

Exclusion criteria

* Known inflammatory bowel disease * Known autoimmune disease. * Chronic pain patient. * Pregnant or breastfeeding. * In treatment with systemic corticoid steroids or immune-depressants. * Known glaucoma. * Known ocular herpes simplex. * Vaccination within 14 days prior to inclusion. * Known cushing's disease. * Known myasthenia gravis. * Presumably poor compliance with study protocol.

Design outcomes

Primary

MeasureTime frameDescription
Postoperative nausea and vomiting (PONV)24-32 hours postoperativeIncidents of nausea and/or vomiting during the first 24-32 hours postoperative

Secondary

MeasureTime frameDescription
Time until resumption of normal daily activitiesRegistration when resumption, expected to be within 60 days postoperativelyTime until resumption of normal daily activities and reason for not resuming activities earlier
Duration of admission30 daysDuration of primary admission
PONV2-10 hours postoperatively
Postoperative fatigue (VAS scale24-32 hours postoperativePostoperative fatigue measured on a 100 mm VAS scale
Pain at rest (VAS scale)2-10 hours postoperativePain at rest measured on a 100 mm VAS scale
Postoperative fatigue (VAS scale)2-10 hours postoperativePostoperative fatigue measured on a 100 mm VAS scale
Quality of recovery (QoR-15D questionnaire)24-32 hours postoperativeQuality of recovery measured by the QoR-15D questionnaire
Pain when coughing (VAS scale)2-10 hours postoperativePain when coughing measured on a 100 mm VAS scale
Time until resumption of workRegistration when resumption, expected to be within 60 days postoperativelyTime until resumption of work and reason for not resuming work earlier
Sleep quality (VAS scale)24-32 hours postoperativeQuality of sleep measured on a 100 mm VAS scale
Postoperative complications (Clavien-Dindo classification of surgical complications)30 days postoperative30 days postoperative complication according to the Clavien-Dindo classification of surgical complications

Other

MeasureTime frameDescription
Pain localization (Localization of postoperative pain)2-10 hours postoperativeLocalization of postoperative pain
Adverse events30 daysAE, AR, SAR and SUSARS
Mobilisation postoperative (Ability to get out of bed)2-10 hours postoperativeAbility to get out of bed

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026